Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers

Study Identifier:
E-78097791-020-5767
ClinicalTrials.gov Identifier:
NCT07736976
EudraCT Identifier:
N/A
Will Be Recruiting

Study Details

Medical Condition
  • Hemophilia A and B
Study Drug
    Date
    Aug 2026 - Sep 2026
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Male
    Age: 18 - 35 Years years
    Requirements Information
    Inclusion and Exclusion Criteria
    Inclusion Criteria
    • Hemophilia Group:
    • Diagnosis of hemophilia A or hemophilia B
    • Age between 18 and 35 years
    • Ability to walk independently
    • Willingness to participate in the study voluntarily
    • Healthy Control Group:
    • Age between 18 and 35 years
    • No history of hemophilia or other bleeding disorders
    • No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
    • No neurological, rheumatological, or severe orthopedic disorders
    • Willingness to participate in the study voluntarily
    Exclusion Criteria
    • Hemophilia Group:
    • \- Acute joint bleeding episode within the previous 3 months

    Protocol Summary

    This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

    Trial Locations

    Location
    Status
    Location
    Bahcesehir university
    Istanbul, Istanbul, Turkey, 34353
    Status
    N/A